Black Diamond Therapeutics, Inc.
General ticker "BDTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $145.9M (TTM average)
Black Diamond Therapeutics, Inc. follows the US Stock Market performance with the rate: 44.1%.
Estimated limits based on current volatility of 3.1%: low 2.82$, high 3.00$
Factors to consider:
- Total employees count: 24 (-55.6%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Cybersecurity threats, Geopolitical risks, Limited resources, Environmental regulations
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.82$, 4.61$]
- 2026-12-31 to 2027-12-31 estimated range: [2.21$, 5.28$]
Financial Metrics affecting the BDTX estimates:
- Positive: with PPE of 5.1 at the end of fiscal year the price was very low
- Positive: Operating cash flow per share per price, % of 20.43 > 12.96
- Positive: Operating profit margin, % of 28.39 > 18.52
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.52 > 6.12
- Negative: negative Industry operating cash flow (median)
Short-term BDTX quotes
Long-term BDTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $70.00MM |
| Operating Expenses | $86.46MM | $78.78MM | $50.13MM |
| Operating Income | $-86.46MM | $-78.78MM | $19.87MM |
| Non-Operating Income | $4.02MM | $9.11MM | $2.50MM |
| R&D Expense | $59.35MM | $51.31MM | $33.56MM |
| Income(Loss) | $-82.44MM | $-69.68MM | $22.37MM |
| Profit(Loss)* | $-82.44MM | $-69.68MM | $22.37MM |
| Stockholders Equity | $116.74MM | $83.28MM | $112.21MM |
| Assets | $158.57MM | $122.64MM | $143.01MM |
| Operating Cash Flow | $-66.72MM | $-62.30MM | $29.61MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $16.35MM | $16.97MM | $-44.91MM |
| Financing Cash Flow | $71.93MM | $25.55MM | $-0.15MM |
| Earnings Per Share** | $-1.88 | $-1.27 | $0.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.